RARE DISEASERESEARCH ATLAS

ORPHA:52901

Isolated follicle stimulating hormone deficiency

high confidenceDisorder

Also known as: Isolated FSH deficiency

Publications

74

41.2th percentile

Trials

0

Interventional, condition-specific

Researchers

331

Distinct authors in sample

Gene link

FSHB

Strong

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare hypogonadotropic hypogonadism characterized by hypogonadism due to selective deficiency of follicle stimulating hormone (FSH). Clinical manifestations are primary amenorrhea, absent or incomplete breast development, and infertility in women, and small testes, azoospermia, and infertility in men. Luteinizing hormone is elevated in the gonadotropin-releasing hormone stimulation test, while the FSH response is impaired.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

FSHB hypogonadotropic hypogonadism · hypogonadotropic hypogonadism 24 without anosmia · hypogonadotropic hypogonadism caused by mutation in FSHB · isolated FSH deficiency

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — FSHB

  2. LiteraturePresent

    74 matched papers (26 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (FSHB).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

74

74 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

74 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

26 in the last 10 years · high confidence · 41.2th percentile (publications denominator)

Phrase hits: 74 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

331

Distinct author names in 74 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Layman LC8 papers · 2020

    Section of Reproductive Endocrinology, Infertility, & Genetics, Department of Obstetrics & Gynecology, Institute of Molecular Medicine and Genetics, Neuroscience Program, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA. lalayman@gru.edu

    Papers in Europe PMC
  2. 02
    Grigorova M3 papers · 2011

    Human Molecular Genetics Research Group, Institute of Molecular and Cell Biology, University of Tartu, 51010 Tartu, Estonia.

    Papers in Europe PMC
  3. 03
    Laan M3 papers · 2011
    Papers in Europe PMC
  4. 04
    Latronico AC3 papers · 2022

    Department of Internal Medicine, Discipline of Endocrinology and Metabolism, Sao Paulo Medical School, University of Sao Paulo, Sao Paulo, Brazil.

    Papers in Europe PMC
  5. 05
    Ausmees K2 papers · 2011
    Papers in Europe PMC
  6. 06
    Barnes RB2 papers · 2002

    Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA. rbarnes@babies.bsd.uchicago.edu

    Papers in Europe PMC
  7. 07
    Benveniste R2 papers · 1979
    Papers in Europe PMC
  8. 08
    Bernard DJ2 papers · 2018

    Department of Pharmacology & Therapeutics, McGill University, Montréal, Québec, Canada.

    Papers in Europe PMC
  9. 09
    Boehm U2 papers · 2018

    Department of Experimental Pharmacology, Center for Molecular Signaling, Saarland University School of Medicine, Homburg, Germany.

    Papers in Europe PMC
  10. 10
    Boerboom D2 papers · 2018

    Département de Biomédecine Vétérinaire, Université de Montréal, St-Hyacinthe, Québec, Canada.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Isolated follicle stimulating hormone deficiency" OR "Isolated FSH deficiency" OR "FSHB hypogonadotropic hypogonadism" OR "hypogonadotropic hypogonadism 24 without anosmia" OR "hypogonadotropic hypogonadism caused by mutation in FSHB"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Follicle-stimulating hormone deficiency, isolated

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Isolated follicle stimulating hormone deficiency" OR "Isolated FSH deficiency" OR "FSHB hypogonadotropic hypogonadism" OR "hypogonadotropic hypogonadism 24 without anosmia" OR "hypogonadotropic hypogonadism caused by mutation in FSHB" OR "Follicle-stimulating hormone deficiency, isolated" OR "FSHB"

Recall-expansion terms: FSHB

Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, recall-expansion

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T00:50:33.535Z